Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not yet recruiting

Evaluation of Alutard SQ dog allergen immunotherapy in patients with allergic rhinitis due to dog allergy - A one-year study in Swedish practice

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study focuses on treating allergic rhinitis caused by dog allergies. The main treatment being tested is Alutard SQ dog, which is given as an injection under the skin. The study aims to determine how well this treatment improves allergy symptoms in people who are allergic to dogs after one year of treatment. Additional medications that may be used during the study include Nasonex nasal spray, Livostin eye drops, and Desloratadine tablets.

The treatment involves receiving injections of Alutard SQ dog, which contains small amounts of dog allergens. These allergens are substances from dogs that cause allergic reactions in some people. During the study, participants may also use other allergy medications to help manage their symptoms. The study will last for approximately one year.

The researchers will measure how well the treatment works by checking changes in nasal symptoms and using a rating scale to assess allergy symptoms when exposed to dog dander. They will also monitor breathing ability and check for any changes in eye symptoms. Throughout the study, doctors will keep track of any side effects that may occur during the treatment.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial treatment phase

    You will begin receiving Alutard SQ dog treatment through subcutaneous injections (injections under the skin).

    The treatment involves regular injections to gradually increase your tolerance to dog allergens.

    You will be provided with nasal spray (Nasonex), eye drops (Livostin), and tablets (Desloratadine) to help manage allergy symptoms as needed.

  2. Step 2

    Symptom monitoring

    Your allergy symptoms will be evaluated using a total nasal symptom score and a visual scale.

    These evaluations will occur 30 minutes after exposure to dog allergens.

    Your breathing will be measured using special devices to check nasal airflow and lung function.

  3. Step 3

    Ongoing treatment

    The treatment will continue for one year.

    Regular assessments will track your progress and any side effects.

    Blood tests will be conducted to measure specific antibody levels related to dog allergies.

  4. Step 4

    Final evaluation

    After one year of treatment, your response to dog allergens will be tested again.

    The final assessment will compare your symptom scores and breathing measurements to those taken at the start of the study.

    The effectiveness of the treatment will be determined by measuring improvements in your allergy symptoms.

Who can join the trial?

6 criteria

  • You must provide written consent to participate in the trial
  • You must be between 18 and 50 years old
  • You must have moderate to severe allergic symptoms when exposed to dogs (such as sneezing, runny nose, itchy eyes, or breathing difficulties)
  • A doctor must determine that you are suitable for treatment with Alutard SQ Dog (an allergy medication)
  • If you are a woman who can become pregnant, you must:
    • Use effective contraception (birth control) during the study
    • Have a negative pregnancy test before starting the trial

Who cannot join the trial?

15 criteria

  • Age below 18 or above 65 years
  • Previous treatment with immunotherapy (allergy shots) for dog allergy in the past 5 years
  • Pregnancy or planning to become pregnant during the study period
  • Severe asthma (a condition affecting breathing)
  • Current treatment with beta-blockers (certain heart and blood pressure medications)
  • Serious heart or lung conditions
  • Active autoimmune diseases (conditions where the immune system attacks the body)
  • History of severe allergic reactions requiring emergency treatment
  • Current participation in other clinical trials
  • Inability to follow study procedures or attend scheduled visits
  • Serious mental health conditions that could affect participation
  • Use of medications that could interfere with the study treatment
  • History of anaphylaxis (severe, life-threatening allergic reaction)
  • Unstable medical conditions requiring frequent medication changes
  • Poor compliance with current medical treatments
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Alutard SQ dog is an allergen immunotherapy medication used to treat allergies to dogs. It works by gradually exposing the patient to small amounts of dog allergens, helping the immune system become less sensitive over time. This treatment aims to reduce allergic symptoms such as sneezing, runny nose, itchy eyes, and breathing difficulties that occur when exposed to dogs. The medication is administered through injections over an extended period to build up tolerance to dog allergens.

What is already known about the treatment

Alutard SQ dog - A prescription allergen immunotherapy medication administered through subcutaneous injections for treating allergic rhinitis specifically caused by dog allergies. This allergen-specific immunotherapy works by gradually exposing the immune system to increasing amounts of dog allergen, helping to build tolerance and reduce allergic reactions over time. The medication belongs to the class of allergy desensitization treatments and modifies the body's immune response at the cellular level by inducing regulatory T-cells and shifting the immune response from allergic to tolerogenic patterns. Note: My response is based on the clinical trial information provided, focusing on the medication mentioned in the trial objective. The description is written in clear English, avoiding complex medical terminology while maintaining accuracy and following the requested format.

Investigated diseases

Allergic rhinitis due to dog allergy - A type of allergic reaction that occurs when a person is exposed to proteins found in dog dander, saliva, or urine. This condition causes inflammation of the nasal passages, leading to symptoms such as sneezing, runny nose, nasal congestion, and itchy nose. The symptoms typically begin shortly after exposure to dog allergens and can persist as long as the exposure continues. Some people may also experience eye symptoms like itching, redness, and watering, as well as breathing difficulties. The condition is caused by an overreaction of the immune system to otherwise harmless dog proteins.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-517649-15-00Protocol codeALLERDOGEstimated enrolment40 patientsSponsorKarolinska Institutet

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.